Roche Holdings Ltd ADR (RHHBY)

$57.11 -0.59 (-1.02%)
Market Cap 367.58B
Revenue (ttm) 76.45B
Net Income (ttm) 15.54B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 18.12
Profit Margin 20.33%
Debt to Equity Ratio 1.00
Volume 3,509,200
Avg Vol 2,766,894
Day's Range N/A - N/A
Shares Out 6.37B
Stochastic %K 76%
Beta 0.44
Analysts Sell
Price Target $52.72

Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer,...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 41 61 688 88 80
Fax: 41 61 691 00 14
Address:
Grenzacherstrasse 124, Basel, Switzerland
toyboy67
toyboy67 Mar. 15 at 9:56 AM
$RHHBY I have been taking Evrysdi for quite some time now, and my total treatment costs (Spinraza/Evrysdi) already exceed $2 million USD. I have been in inpatient rehabilitation for 10 weeks and am loading my muscles daily. The healthy muscles are getting stronger, and the affected muscle groups are being reactivated and starting to work again. I am reaching milestones that I was not able to achieve before. This motivates me to keep going. The rehab costs approximately $8,000–$10,000 USD per month, but I have top therapists who push me, monitor me, and observe me closely. Leg press, butterfly, cable pulls and more are all part of it. According to the senior and chief physicians in Germany, I am the only person with this condition who is really going all in and fully committed.
1 · Reply
JuggernautRaider
JuggernautRaider Mar. 14 at 11:10 PM
$ALT I agree that NVO and $RHHBY would be likely acquirers following the phase 2 for AUD at the higher 2.4mg dose - ESPECIALLY if the weight loss improves upon the 8% seen at the 1.8mg dose in the Ph2B trial. Also $AZ and $PFE . I don’t think LLY is as likely. They are a Juggernaut across the board 🏃‍♂️
0 · Reply
scotttrader213
scotttrader213 Mar. 13 at 4:40 PM
$RHHBY looking to add under 48
0 · Reply
Quantumup
Quantumup Mar. 13 at 3:09 PM
BofA⬆️ Mineralys' PT to $51 from $46 and reiterated at a Buy, separately Stifel on $MLYS said: We reiterate our Buy rating, $52 TP. $AZN $ALNY - $RHHBY $NVS Here's what else Stifel had to say: https://x.com/Quantumup1/status/2032473479035936901?s=20
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 9:43 PM
$RHHBY take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
Quantumup
Quantumup Mar. 12 at 3:31 PM
Wolfe Research on $CELC (Outperform; $110) said, Competitor's Data Unchanged; Maintain OP on CELC $RLAY $RHHBY $LLY $BBOT BGNE NVS Here's what else Wolfe Research had to say in its note to investors: https://x.com/Quantumup1/status/2032116442045231572?s=20
0 · Reply
Quantumup
Quantumup Mar. 10 at 1:27 PM
Needham⬆️the PT on $CELC to $122 from $95 and reiterated at a Buy $RLAY $RHHBY LLY $AZN $NVS PFE Needham said—Celcuity announced yesterday that the NDA for gedatolisib received priority review, with a PDUFA date of July 17, 2026. Additionally, the company announced the publication of results from the PIK3CA WT cohort of the VIKTORIA-1 study evaluating gedatolisib-based regimens in HR+/HER2- mBC in the Journal of Clinical Oncology. The detailed results were consistent with prior disclosures, while demonstrating a trending benefit in OS. Given the potential for an earlier approval, we reiterate our Buy Rating and are increasing our Price Target from $95 to $122.
0 · Reply
scotttrader213
scotttrader213 Mar. 10 at 12:41 PM
$RHHBY Roche moved five drugs from midstage to late-stage trials last year and all five sit in its most promising pipeline bucket, with peak sales estimated at above 3 billion Swiss francs,
0 · Reply
snowboy
snowboy Mar. 9 at 2:40 PM
$CAPR Should be an interesting news week for us. Of interest Roche's estrogen degrader drug failed to meet endpoints, causing a 5% drop. I'm still betting on $RHHBY for Linda's buyout or partner company. Clout in US and Europe with regulators, sales forces, etc.
1 · Reply
ZacksResearch
ZacksResearch Mar. 9 at 2:35 PM
$RHHBY missed primary endpoint in breast cancer study — is the stock still a buy? The phase III persevERA study failed to show a statistically significant improvement in progression-free survival, but the company remains optimistic about giredestrant's long-term potential and ongoing trials. Discover the full details and implications here 👉 https://www.zacks.com/stock/news/2880934/roches-giredestrant-misses-key-goal-in-first-line-breast-cancer-study?cid=sm-stocktwits-2-2880934-body-36566&ADID=SYND_STOCKTWITS_TWEET_2_2880934_BODY_36566
0 · Reply
Latest News on RHHBY
No data available.
toyboy67
toyboy67 Mar. 15 at 9:56 AM
$RHHBY I have been taking Evrysdi for quite some time now, and my total treatment costs (Spinraza/Evrysdi) already exceed $2 million USD. I have been in inpatient rehabilitation for 10 weeks and am loading my muscles daily. The healthy muscles are getting stronger, and the affected muscle groups are being reactivated and starting to work again. I am reaching milestones that I was not able to achieve before. This motivates me to keep going. The rehab costs approximately $8,000–$10,000 USD per month, but I have top therapists who push me, monitor me, and observe me closely. Leg press, butterfly, cable pulls and more are all part of it. According to the senior and chief physicians in Germany, I am the only person with this condition who is really going all in and fully committed.
1 · Reply
JuggernautRaider
JuggernautRaider Mar. 14 at 11:10 PM
$ALT I agree that NVO and $RHHBY would be likely acquirers following the phase 2 for AUD at the higher 2.4mg dose - ESPECIALLY if the weight loss improves upon the 8% seen at the 1.8mg dose in the Ph2B trial. Also $AZ and $PFE . I don’t think LLY is as likely. They are a Juggernaut across the board 🏃‍♂️
0 · Reply
scotttrader213
scotttrader213 Mar. 13 at 4:40 PM
$RHHBY looking to add under 48
0 · Reply
Quantumup
Quantumup Mar. 13 at 3:09 PM
BofA⬆️ Mineralys' PT to $51 from $46 and reiterated at a Buy, separately Stifel on $MLYS said: We reiterate our Buy rating, $52 TP. $AZN $ALNY - $RHHBY $NVS Here's what else Stifel had to say: https://x.com/Quantumup1/status/2032473479035936901?s=20
0 · Reply
truehealthvalue
truehealthvalue Mar. 12 at 9:43 PM
$RHHBY take a look at $ELTX CEO comment 30’ ago: “Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial” The previous comment by Elicios CEO is key: he is telling you that the results are guaranteed to be good, better than anything currently available. This company could be one of the best investments in the history of biotechnology. It is certainly worth much more than its current valuation. I will Increase my position
0 · Reply
Quantumup
Quantumup Mar. 12 at 3:31 PM
Wolfe Research on $CELC (Outperform; $110) said, Competitor's Data Unchanged; Maintain OP on CELC $RLAY $RHHBY $LLY $BBOT BGNE NVS Here's what else Wolfe Research had to say in its note to investors: https://x.com/Quantumup1/status/2032116442045231572?s=20
0 · Reply
Quantumup
Quantumup Mar. 10 at 1:27 PM
Needham⬆️the PT on $CELC to $122 from $95 and reiterated at a Buy $RLAY $RHHBY LLY $AZN $NVS PFE Needham said—Celcuity announced yesterday that the NDA for gedatolisib received priority review, with a PDUFA date of July 17, 2026. Additionally, the company announced the publication of results from the PIK3CA WT cohort of the VIKTORIA-1 study evaluating gedatolisib-based regimens in HR+/HER2- mBC in the Journal of Clinical Oncology. The detailed results were consistent with prior disclosures, while demonstrating a trending benefit in OS. Given the potential for an earlier approval, we reiterate our Buy Rating and are increasing our Price Target from $95 to $122.
0 · Reply
scotttrader213
scotttrader213 Mar. 10 at 12:41 PM
$RHHBY Roche moved five drugs from midstage to late-stage trials last year and all five sit in its most promising pipeline bucket, with peak sales estimated at above 3 billion Swiss francs,
0 · Reply
snowboy
snowboy Mar. 9 at 2:40 PM
$CAPR Should be an interesting news week for us. Of interest Roche's estrogen degrader drug failed to meet endpoints, causing a 5% drop. I'm still betting on $RHHBY for Linda's buyout or partner company. Clout in US and Europe with regulators, sales forces, etc.
1 · Reply
ZacksResearch
ZacksResearch Mar. 9 at 2:35 PM
$RHHBY missed primary endpoint in breast cancer study — is the stock still a buy? The phase III persevERA study failed to show a statistically significant improvement in progression-free survival, but the company remains optimistic about giredestrant's long-term potential and ongoing trials. Discover the full details and implications here 👉 https://www.zacks.com/stock/news/2880934/roches-giredestrant-misses-key-goal-in-first-line-breast-cancer-study?cid=sm-stocktwits-2-2880934-body-36566&ADID=SYND_STOCKTWITS_TWEET_2_2880934_BODY_36566
0 · Reply
IndyOne
IndyOne Mar. 9 at 2:17 PM
$MRNA October 2025: STET rumored Moderna "deal of significant scope" in discussion, buyout or massive partnership. December 2025: Stéphane Bancel and his wife, Moderna CEO, sold his six-level home in Boston where he has lived for +12 years. January 2026: Moderna and Merck announced five-year follow-up data from the Phase 2b KEYNOTE-942 trial showed a 49% reduction in the risk of recurrence or death. Keytruda goes off patent soon, Merck can use Moderna's mRNA-4157 (also known as V940 or intismeran autogene) a first-of-its-kind, personalized mRNA cancer vaccine to extend Keytruda protection. February 2026: Patent litigation resolved with payment from Moderna. Moderna wanted the decks clear, they could have fought this longer like Pfizer & Biontech. NO ROYALTIES! HUGE WIN. News coming. Big. Could involve $JNJ $MRK $RHHBY $AZN
0 · Reply
ZacksResearch
ZacksResearch Mar. 9 at 1:35 PM
$RHHBY just hit a clinical setback — and investors should pay attention Giredestrant plus palbociclib missed the main PFS goal in a phase III first-line breast cancer study, though the combo showed a numerical improvement. Find out what this means for the pipeline 👉 https://www.zacks.com/stock/news/2880934/roches-giredestrant-misses-key-goal-in-first-line-breast-cancer-study?cid=sm-stocktwits-2-2880934-teaser-36539&ADID=SYND_STOCKTWITS_TWEET_2_2880934_TEASER_36539
0 · Reply
scotttrader213
scotttrader213 Mar. 9 at 12:19 PM
$RHHBY Roche (RHHBF) (RHHBY) shares fell after the Swiss drugmaker’s investigational breast cancer pill failed to meet the primary goal of a late-stage breast cancer trial.
0 · Reply
DonCorleone77
DonCorleone77 Mar. 8 at 6:28 PM
$RHHBY Roche Chairman says diagnostics division exposed to tariffs, Reuters says Roche believes that while its agreement with the U.S. government will keep its medicines exempt from the current round of import tariffs, its diagnostics division remains exposed and may face renewed duties after an initial 150-day period, Reuters reports, citing statement made by Chairman Severin Schwan.
0 · Reply
scotttrader213
scotttrader213 Mar. 7 at 1:51 AM
$RHHBY holding steady. The vast potential with GLP-1 good become a game changer
0 · Reply
ZacksResearch
ZacksResearch Mar. 6 at 6:50 PM
$RHHBY just cleared a key hurdle in the obesity race. The ZUPREME-1 study met its goal, with petrelintide delivering up to 10.7% weight loss and placebo-like tolerability — a combo that supports further advancement of the pipeline. See what this could mean for the drug’s path forward 👉 https://www.zacks.com/stock/news/2880236/roche-advances-obesity-pipeline-as-petrelintide-meets-phase-ii-goal?cid=sm-stocktwits-2-2880236-teaser-36440&ADID=SYND_STOCKTWITS_TWEET_2_2880236_TEASER_36440
0 · Reply
ZacksResearch
ZacksResearch Mar. 6 at 5:50 PM
$RHHBY makes strides in obesity treatment with petrelintide! 🚀 ✅ Phase II ZUPREME-1 study met primary endpoint with up to 10.7% mean weight loss at 42 weeks. 🤝 Co-developed with $ZEAL, showing placebo-like tolerability and potential for chronic weight management. Discover strategic potential within Roche's cardiometabolic pipeline 👉 https://www.zacks.com/stock/news/2880236/roche-advances-obesity-pipeline-as-petrelintide-meets-phase-ii-goal?cid=sm-stocktwits-2-2880236-body-36406&ADID=SYND_STOCKTWITS_TWEET_2_2880236_BODY_36406
0 · Reply
chuckieclam
chuckieclam Mar. 5 at 9:25 PM
$VKTX some dope is on twitter talking shit. Bioinvestor24 @bioinvestor24 So I guess I was too optimistic on my estimates $ZEAL $RHHBY amylin. Conclusion GLP1 GIP reigns. Can we stop calling amylin “Next generation “ $VKTX dual agonist results in deep wt loss to a point of de escalation in some pts before wk 30 .. Roche is all in obesity and metabolism and if the combo with CT388 doesn’t work well ( tolerability ) expect them to do another M&A by next year. Still contest between $LLY tirzepatide and VK 2735 long term.
0 · Reply
biolover
biolover Mar. 5 at 7:28 PM
$VKTX So I guess I was too optimistic on my estimates $ZEAL $RHHBY amylin. Conclusion GLP1 GIP reigns. Can we stop calling amylin “Next generation “ $VKTX dual agonist results in deep wt loss to a point of de escalation in some pts before wk 30 .. Roche is all in obesity and metabolism and if the combo with CT388 doesn’t work well ( tolerability ) expect them to do another M&A by next year. Still contest between $LLY tirzepatide and VK 2735 long term.
2 · Reply
Quantumup
Quantumup Mar. 5 at 1:09 PM
H.C. Wainwright⬆️ $EYPT to $30 and reiterated at Buy after the Co reported 4Q/FY finacial results/announced earlier this week that the Ph3 trials of DURAVYU in DME had dosed the first patients. $OCUL $REGN $RHHBY FDMT KOD $SRZN H.C. Wainwright said—Management noted that DURAVYU could potentially address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME. Both COMO and CAPRI trials could report topline data in 2H27, according to management. In the wake of this update, we have included the Phase 3 DME program in our valuation and our estimated market value of the firm has increased to $2.51B, or approximately $30 per share. Therefore, we reiterate our Buy rating while raising our 12-month price target to $30 from $23 per share.
0 · Reply
BioRich
BioRich Mar. 4 at 10:56 PM
$VERU Haven't forgotten about you. Keep preserving that muscle and let's get a damn deal done! Here are some highlights from the upcoming "4th Obesity & Weight Loss Drug Development Summit." (July 14th-16) The summit specifically highlights $VERU in the same bullets as $NVO, $LLY and $RHHBY and calling them "Innovative Biotech" along with Canary and $MTSR For those interested, here's the link to the Summit and downloading the Agenda is free with this link: Summit Link: https://obesity-weight-loss-summit.com/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01 Event Guide Link: https://obesity-weight-loss-summit.com/full-event-guide/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01
1 · Reply
nostic
nostic Mar. 4 at 8:06 PM
$RHHBY $PFE $LLY check out $CGTX... big things coming together there in AD & DLB. Approaching prime time for a partnership.
2 · Reply